Cognition Therapeutics (CGTX) vs Cardiff Oncology (CRDF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Cardiff Oncology (CRDF) has outperformed Cognition Therapeutics (CGTX) over the past year, losing 54.6% versus a loss of 55.0%. Over five years, CRDF leads with a -83.1% price change compared with -92.6% for CGTX. Cardiff Oncology is the larger company by market cap ($84.0 million vs $83.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGTX | CRDF |
|---|---|---|
| Share price | $0.8769 | $1.08 |
| Market cap | $83.39M | $84.02M |
| 1-day change | -2.04% | +1.89% |
| YTD return | -35.04% | -61.57% |
| 1-year return | -55.03% | -54.62% |
| 5-year return | -92.63% | -83.13% |
| EPS (TTM) | $-0.17 | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.00 | $3.31 |
| 52-week low | $0.55 | $0.76 |
| Distance from 52-week high | -56.16% | -67.37% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +279.75% | +437.96% |
| Average volume | 515.55K | 1.04M |
| Shares outstanding | 95.09M | 77.80M |
| Employees | 14 | 30 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cognition Therapeutics
CGTX stock →Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
About Cardiff Oncology
CRDF stock →Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees
CGTX vs CRDF FAQ
Which is bigger, Cognition Therapeutics or Cardiff Oncology?
Cardiff Oncology (CRDF) is larger, with a market capitalization of $84.02M compared with $83.39M for Cognition Therapeutics (CGTX).
Which stock has performed better over the past year, CGTX or CRDF?
CRDF returned -54.62% over the past 12 months, compared with -55.03% for CGTX (price return, excluding dividends). Past performance does not predict future results.
Are Cognition Therapeutics and Cardiff Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.